Ribociclib
Chemotherapy

The combination of CDK4/6 inhibitors with endocrine therapy for estrogen receptor (ER)-positive, human epidermal growth factor 2 (HER2)-negative metastatic breast cancer (MBC) continues to be among the most successful stories in treatment for advanced disease.

How have these drugs changed the MBC treatment landscape. "Most people use cyclin-dependent kinase (CDK) 4/6 inhibitors at the time of first metastatic

link to paper

Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies, 2019